Roche & Generic Firms Propose SMART-er Accutane Risk Management Program
This article was originally published in The Pink Sheet Daily
Executive Summary
"Consensus proposal" includes mandatory registration of female patients and prescribers. The proposed enhancements to SMART incorporate aspects of Celgene's STEPS program for Thalomid, but avoid restricted distribution.
You may also be interested in...
Accutane Risk Management Program Changes Held Up By Celgene Patents
Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).